Palladio Biosciences, Inc., A Centessa Company
Get verified emails for Palladio Biosciences, Inc., A Centessa Company employees
About Palladio Biosciences, Inc., A Centessa Company
Palladio Biosciences, Inc., is a Centessa company. Our first product, lixivaptan, is in Phase 3 clinical development for the treatment of autosomal polycystic kidney disease (ADPKD). ADPKD causes numerous fluid-filled cysts to grow in both kidneys. It is a life-limiting, chronic and progressive disease. It is the 4th leading cause of kidney failure and carries significant financial and emotional burden, affecting entire families.
There is no cure for PKD. We are developing lixivaptan as a safe and effective agent to be used chronically to prevent the progression of PKD.
|
|
|
|
|
Biotechnology
|
|
5 Walnut Grove Drive, Suite 120, Horsham, Pennsylvania 19044, US
|
|
2015
|
|
Nephrology, Kidney Disease, Rare, Renal Disease, Polycystic Kidney Disease, Pkd, Orphan, Adpkd, Genetic Disease, Arpkd
|
Palladio Biosciences, Inc., A Centessa Company Staff Directory
Search Palladio Biosciences, Inc., A Centessa Company Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.
